Cogent Biosciences Inc

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. Its most advanced clinical program is bezuclastinib, a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation and other KIT exon 17 mutations. KIT D816V drives systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST). The company has submitted three New Drug Applications for bezuclastinib across GIST, non-advanced systemic mastocytosis (NonAdvSM), and advanced systemic mastocytosis (AdvSM). Beyond bezuclastinib, Cogent's research team is developing a portfolio of novel targeted therapies for serious genetically driven diseases, targeting mutations in ErbB2 (CGT4255), PI3Kα, KRAS (CGT1815), and JAK2 (CGT1145). The company is pre-revenue and trades on the Nasdaq under the ticker COGT. Updated Aug 10, 2026